Phase II trial of 4′-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer

Ted Braich; Frederick R. Ahmann; Harinder S. Garewal; Aurelia Robertone; Sydney E. Salmon

doi:10.1007/BF00194602

Phase II trial of 4′-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer

Ted Braich, Frederick R. Ahmann, Harinder S. Garewal, Aurelia Robertone, Sydney E. Salmon

Cancer Center

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Fifteen patients with hormone resistant advanced prostate cancer were treated with anthracycline analog 4′-deoxydoxorubicin (Esorubicin). No patient had objective evidence of tumor regression. Six patients (40%) were classified using the National Prostatic Cancer Project criteria as having stable disease after two courses of therapy. Treatment was associated with significant hematologic toxicity with 50% of patients experiencing grade III or IV neutropenia. Clinical cardiac toxicity was not observed. Further trials of 4′ -deoxydoxorubicin do not appear to be warranted in advanced prostate cancer.

Original language	English (US)
Pages (from-to)	193-196
Number of pages	4
Journal	Investigational New Drugs
Volume	4
Issue number	2
DOIs	https://doi.org/10.1007/BF00194602
State	Published - Jun 1986

Keywords

4′-deoxydoxorubicin
phase II
prostate cancer

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00194602

Cite this

@article{8e6bf3ab80a34ca9bc1ac362af25ef11,

title = "Phase II trial of 4′-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer",

abstract = "Fifteen patients with hormone resistant advanced prostate cancer were treated with anthracycline analog 4′-deoxydoxorubicin (Esorubicin). No patient had objective evidence of tumor regression. Six patients (40\%) were classified using the National Prostatic Cancer Project criteria as having stable disease after two courses of therapy. Treatment was associated with significant hematologic toxicity with 50\% of patients experiencing grade III or IV neutropenia. Clinical cardiac toxicity was not observed. Further trials of 4′ -deoxydoxorubicin do not appear to be warranted in advanced prostate cancer.",

keywords = "4′-deoxydoxorubicin, phase II, prostate cancer",

author = "Ted Braich and Ahmann, \{Frederick R.\} and Garewal, \{Harinder S.\} and Aurelia Robertone and Salmon, \{Sydney E.\}",

year = "1986",

month = jun,

doi = "10.1007/BF00194602",

language = "English (US)",

volume = "4",

pages = "193--196",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Phase II trial of 4′-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer

AU - Braich, Ted

AU - Ahmann, Frederick R.

AU - Garewal, Harinder S.

AU - Robertone, Aurelia

AU - Salmon, Sydney E.

PY - 1986/6

Y1 - 1986/6

N2 - Fifteen patients with hormone resistant advanced prostate cancer were treated with anthracycline analog 4′-deoxydoxorubicin (Esorubicin). No patient had objective evidence of tumor regression. Six patients (40%) were classified using the National Prostatic Cancer Project criteria as having stable disease after two courses of therapy. Treatment was associated with significant hematologic toxicity with 50% of patients experiencing grade III or IV neutropenia. Clinical cardiac toxicity was not observed. Further trials of 4′ -deoxydoxorubicin do not appear to be warranted in advanced prostate cancer.

AB - Fifteen patients with hormone resistant advanced prostate cancer were treated with anthracycline analog 4′-deoxydoxorubicin (Esorubicin). No patient had objective evidence of tumor regression. Six patients (40%) were classified using the National Prostatic Cancer Project criteria as having stable disease after two courses of therapy. Treatment was associated with significant hematologic toxicity with 50% of patients experiencing grade III or IV neutropenia. Clinical cardiac toxicity was not observed. Further trials of 4′ -deoxydoxorubicin do not appear to be warranted in advanced prostate cancer.

KW - 4′-deoxydoxorubicin

KW - phase II

KW - prostate cancer

UR - https://www.scopus.com/pages/publications/0022497965

UR - https://www.scopus.com/inward/citedby.url?scp=0022497965&partnerID=8YFLogxK

U2 - 10.1007/BF00194602

DO - 10.1007/BF00194602

M3 - Article

C2 - 3733379

AN - SCOPUS:0022497965

SN - 0167-6997

VL - 4

SP - 193

EP - 196

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 2

ER -

Phase II trial of 4′-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this